Needle-like sensor helps treat Parkinson’s disease

Academy of Finland developing sensor for neurotransmitter diseases
Medical researcher Emilia Peltola from Aalto University in Finland has helped develop a tiny, needle-like sensor that potentially has a significant role in treating diseases such as depression, chronic pain, Parkinson’s, epilepsy and other diseases caused by neurotransmitter disorders. (Aalto University)

A research team led by Emilia Peltola from Aalto University in Finland are developing a tiny, needle-like sensor that could potentially play a significant role in treating diseases such as depression, chronic pain, Parkinson’s, epilepsy, and other diseases caused by neurotransmitter disorders.

Deep brain stimulation has achieved good results in treating Parkinson’s disease and epilepsy. The therapy involves electrically stimulating the patient’s brain to produce neurotransmitters like dopamine. According to the researchers, adding a sensor to treatment devices installed in the brain would enable physicians to know in real time how the neurotransmitters were responding to treatment. Neurotransmitters are too small to be seen by the naked eye, and therefore no device can directly visualize how they function, forcing us to employ other means to gather information.

"A definite benefit of such sensors would be the real-time nature of the data they produce. Neurotransmitters move from cell to cell very rapidly, and only a real-time method can let us know how much of a specific substance is present at each given moment. Treatments would become more effective, and the risk of adverse effects would reduce," Peltola said in an article appearing on the Aalto University website.  

Sponsored by Digi-Key

Analog Devices ADIS16500/05/07 Precision Miniature MEMS IMU Available Now from Digi-Key

The Analog Devices’ ADI ADIS16500/05/07 precision miniature MEMS IMU includes a triaxial gyroscope and a triaxial accelerometer. Each inertial sensor in the MEMS IMU combines with signal conditioning that optimizes dynamic performance.

In addition to neurotransmitter concentration, it is important to know the location in which neurotransmitters are being released, how rapidly cells are releasing the substance as well as how long it takes for the cell to uptake it. The sensor could fill this information void as existing methods are unable to gather this information. 

The part of the brain in which the sensor is placed determines which neurotransmitter should be measured. The functioning of glutamate, the neurotransmitter that affects learning and memory, is studied in the hippocampus in particular. Local measurements yield real-time information on disease mechanisms as well as on the functioning of the brain and pharmaceuticals.

Peltola believes that if measurements inside the body were to become possible, researchers could develop new diagnostic and treatment methods.

Suggested Articles

Omdia forecast shows AI software declining by 22% because of the pandemic impact on industries like oil and gas

Tests in Germany showed reliability of Cellular Vehicle to Everything, connecting cars to each other and streetlights

Research shows biggest growth expected in Latin America and Asia, as holographic telepresence emerges